Abstract: This invention relates to a size-specific tubing connector assembly used for selectively connecting tubing segments of various inner diameters. A central housing defines at least one through bore between at least first and second ends configured for axial removable engagement with at least a first pair of a plurality of tubular fitments. Each fitment of the at least first pair defines a common inner and outer diameter and is configured for axial alignment in opposition with one another about the housing in series relation to define fitment series “A” and “B” at respective ends of the housing, with the fitments of each series “A” and “B” arranged preferably in a descending order of the respective fitment's outer diameter.

Abstract: This invention relates to an apparatus and method for the dilation of a blood vessel and subcutaneous tissue that eliminates or minimizes a successive and repetitive insertion and removal of multiple, individual dilators necessary to achieve a target dilation. The dilator preferably defines radiopaque markers to make them visible to a medical practitioner via fluoroscopy. A hydrophilic coating is optionally located on the dilator to reduce surface friction and enhance lubricity between the dilator and vessel and/or subcutaneous tissue.

Abstract: This invention relates to the infusion of medications and/or fluids into a patient, and/or the removal of blood samples therefrom. More specifically, this invention relates to an apparatus, system and method of medication/fluid infusion into a patient and/or blood removal from a patient on an extracorporeal membrane oxygenation (ECMO) and/or cardiopulmonary bypass (CPB) fluid circuit such that the need for utilizing a central line, as well as HD or CRRT lines on the patient is avoided.

Abstract: Anti-cancer drugs are identified by screening for agents and compounds which inhibit the binding of HSP90 and IP6K2. In vitro and in vivo assays can be used. Any phenomenon associated with the binding or inhibition can be monitored, including cell death, subcellular localization, catalytic activity of IP6K2, and IP7 formation.

Abstract: Anti-cancer drugs are identified by screening for agents and compounds which inhibit the binding of HSP90 and IP6K2. In vitro and in vivo assays can be used. Any phenomenon associated with the binding or inhibition can be monitored, including cell death, subcellular localization, catalytic activity of IP6K2, and IP7 formation.